Year in Review | Published:

Colorectal cancer in 2017

Practice-changing updates in the adjuvant and metastatic setting

Nature Reviews Clinical Oncology volume 15, pages 7778 (2018) | Download Citation

2017 has been full of new discoveries that will influence the treatment of colorectal cancer. In the adjuvant setting, 3 months of chemotherapy might now be considered a new standard of care. Various other new treatments and promising biomarkers have also become available that will improve survival outcomes and the quality of life of many patients with metastatic disease.

Access optionsAccess options

Rent or Buy article

Get time limited or full article access on ReadCube.

from$8.99

All prices are NET prices.

References

  1. 1.

    et al. Prospective pooled analysis of six phase III trials investigating duration of adjuvant (adjuv) oxaliplatin-based therapy (3 versus 6 months) for patients (pts) with stage III colon cancer (CC): the IDEA (International Duration Evaluation of Adjuvant chemotherapy) collaboration [abstract]. J. Clin. Oncol. 35 (Suppl.), LBA1 (2017).

  2. 2.

    et al. Mismatch repair deficiency predicts response of solid tumors to PD-1 blockade. Science 357, 409–413 (2017).

  3. 3.

    et al. PD-1 blockade in tumors with mismatch-repair deficiency. N. Engl. J. Med. 372, 2509–2520 (2015).

  4. 4.

    et al. Nivolumab in patients with metastatic DNA mismatch repair-deficient or microsatellite instability-high colorectal cancer (CheckMate 142): an open-label, multicentre, phase 2 study. Lancet Oncol. 18, 1182–1191 (2017).

  5. 5.

    et al. Prognostic and predictive value of primary tumour side in patients with RAS wild-type metastatic colorectal cancer treated with chemotherapy and EGFR directed antibodies in six randomized trials. Ann. Oncol. 28, 1713–1729 (2017).

  6. 6.

    et al. Prognostic and predictive relevance of primary tumor location in patients with RAS wild-type metastatic colorectal cancer: retrospective analyses of the crystal and fire-3 trials. JAMA Oncol. 3, 194–201 (2017).

  7. 7.

    et al. Association of primary tumor site with mortality in patients receiving bevacizumab and cetuximab for metastatic colorectal cancer. JAMA Surg. (2017).

  8. 8.

    et al. The consensus molecular subtypes of colorectal cancer. Nat. Med. 21, 1350–1356 (2015).

  9. 9.

    et al. Impact of consensus molecular subtyping (CMS) on overall survival (OS) and progression free survival (PFS) in patients (pts) with metastatic colorectal cancer (mCRC): analysis of CALGB/SWOG 80405 (Alliance) [abstract]. J. Clin. Oncol. 35 (Suppl.), 3511 (2017).

Download references

Author information

Affiliations

  1. Alberto Puccini and Heinz-Josef Lenz are at the Division of Medical Oncology, Suite 3456, Norris Comprehensive Cancer Center, Keck School of Medicine, University of Southern California, 1441 Eastlake Avenue, Los Angeles, California 90033, USA.

    • Alberto Puccini
    •  & Heinz-Josef Lenz

Authors

  1. Search for Alberto Puccini in:

  2. Search for Heinz-Josef Lenz in:

Competing interests

A.P. declares no competing interests. H.-J.L. has received financial support for clinical trials from Merck Serono and Roche, and honoraria for advisory board membership and lectures from Bayer, Boehringer Ingelheim, Genentech, Merck Serono and Roche.

Corresponding author

Correspondence to Heinz-Josef Lenz.

About this article

Publication history

Published

DOI

https://doi.org/10.1038/nrclinonc.2017.185

Further reading

Newsletter Get the most important science stories of the day, free in your inbox. Sign up for Nature Briefing